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This Editorial marks the launch of BMC Hematology, formerly known as BMC Blood Disorders, within the BMC series
of journals published by BioMed Central. The scope of BMC Hematology encompasses basic, experimental and
clinical research related to hematology. In this Editorial we will discuss the rationale behind this relaunch and how,
as an open access journal providing unrestricted and free access to scientific and scholarly work, BMC Hematology
will help disseminate research in the hematology field in a freely-accessible manner.Editorial
Aims and scope
To emphasize its commitment to representing the full
breadth of disciplines and specialties in hematology,
BMC Blood Disorders has relaunched this month under
the name BMC Hematology. The decision to rename the
journal was taken in response to the feedback received
from key opinion leaders in the field and in consultation
with our Editorial Board.
This change of journal name is also intended to reflect
the multi-disciplinary nature of the hematology field in
which rapidly evolving research findings translate into pa-
tient care. Since William Harvey introduced the then con-
troversial concept of circulation in 1628, the field of
hematology has come a long way. Important advances in
the field of molecular biology have enabled fundamental
insights into the origin of human diseases and enabled the
development of innovative treatments. Nowhere are these
changes more prominent than in the field of hematology,
which has indeed paved the way for the thrilling era of
“bench to bedside” research. The past decades have seen
major clinical advances arising from trail-blazing basic re-
search, including hematopoietic stem cell transplantation
for the treatment of blood and bone marrow disorders and
targeted molecular therapies for hematological malignan-
cies. Reflecting the cross-disciplinary and translational na-
ture of the field, BMC Hematology welcomes submissionsCorrespondence: christna.chap@biomedcentral.com
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non-malignant and malignant hematological diseases,
hemostasis and thrombosis, hematopoiesis, stem cells and
transplantation.
BMC Hematology will maintain the ethos of its predeces-
sor and of the rest of its sister journals in the BMC series
[1], and continue to publish work deemed by peer
reviewers to be a coherent and sound addition to scientific
knowledge. There will be less emphasis on interest levels,
provided that the research constitutes a useful contribution
to the field [2]. All previous content will remain freely
accessible from the new journal homepage.
Similarly to other journals in the BMC series, BMC
Hematology has an international Editorial Board of
academic scientists, many of whom are previous members
of BMC Blood Disorders [3]. The journal is divided into a
number of subject-specific sections under the oversight of
Section Editors, who are supported by Associate Editors
and Editorial Advisors as well as in-house Editors. Dividing
the journal into sections not only allows authors to submit
to a specific section but also enables readers to browse
articles in a given area of interest to them [4].
As with BMC Blood Disorders and all other medical
journals within the BMC series, BMC Hematology will op-
erate an open peer review policy with two levels to this
“openness” [5]. The first is that authors will see the
reviewers’ names; the second is that the reading public will
also see who reviewed the article and how the authors
responded, if the article is published. This will be available
as part of the pre-publication history of the published art-
icle. The most important benefits of openness are account-
ability, fairness and giving credit to reviewers for theiris is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the competing interests that can occur during peer review
[6,7].
Open access
Although initially looked upon with skepticism, the open
access publishing model, which provides an unrestricted
and free access to scientific and scholarly work, has become
increasingly accepted as a viable model, with more than
8,500 open access journals now operating worldwide [8].
Open access increases the potential readership of any
article to anyone with internet access and indirectly
accelerates the spread of new research findings. All
articles published in BMC Hematology are included in
the major bibliographic databases including PubMed
and can be freely redistributed and reused as long as
they are correctly attributed. Publication volume has grown
within all major scientific disciplines, but biomedicine has
seen a particularly rapid 16-fold growth between 2000
(7,400 articles) and 2011 (120,900 articles) [9]. Approxi-
mately 17% of all articles published in 2011 are open access.
In a decade, this model has moved from the fringe to the
core of the publishing industry.
Articles published in BMC Hematology will of course be
open access, ensuring that research is disseminated to the
widest possible audience. In order to cover the costs of
publication, an article-processing charge (APC) is levied to
the authors or their institution on acceptance of the art-
icle. This flat fee is among the lowest charged across other
publishers offering open access [10]. Publishing in elec-
tronic format allows the full use of digital technologies
and permits the inclusion of large data sets or video clips
for instance, and unlimited color and page numbers at no
additional charge. If the institute of the authors submitting
a manuscript is a member of BioMed Central, the cost of
the APC is covered by the membership and no further
charge is payable [11]. A number of funding agencies
allow their grants to be used for APCs [12] and waivers
can be granted under special circumstances. Following in
the footsteps of the National Institutes of Health in the
USA, public research funders in the UK have recently
published guidelines to encourage and increase open ac-
cess to publicly funded research [13,14].
Looking ahead
We are delighted to welcome our two first Section
Editors Dan L. Longo from Harvard Medical School and
Mary J. Laughlin from University of Virginia, heading
the Malignant hematological diseases and Hematopoiesis,
stem cells and transplantation sections respectively. We
plan to recruit additional Editorial Board members from
many different disciplines within the hematology field as
well as from different geographic regions. We believe that
a strong Editorial Board is essential to ensure that thejournal is at the forefront of the field while effectively using
the time and effort that the reviewers contribute. In this in-
augural issue, Section Editor Dan L. Longo tells us how he
first became interested in hematology and gives his per-
sonal view on the recent progress and future challenges of
the hematological cancer field in particular [15]. The
relaunch of BMC Hematology marks the start of an exciting
new developmental phase for the journal and we do hope
that you will take the time to visit the website and consider
us for your future submissions.
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